SNDX

Latest SEC Filings & News for SNDX

2 most recent filings and news items mentioning SNDX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/SNDX/news?limit=20"

Pull SNDX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OtherJul 14, 2026Positive

Syndax unveils new pipeline assets SNDX-4321 and SNDX-62122

Syndax Pharmaceuticals unveiled two new pipeline assets, a mutant-selective EGFR inhibitor and a next-generation menin inhibitor, and confirmed the Phase 2 trial of axatilimab is on track for data in 4Q26.

View filing at SEC.gov →

OfferingJun 4, 2026Neutral

Syndax Pharmaceuticals offers convertible senior notes due 2031

Syndax Pharmaceuticals is issuing convertible senior notes due 2031 to accredited and institutional investors without SEC registration. The offering allows conversion into cash, common stock, or a combination thereof at the company's election.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.